JP2022533448A5 - - Google Patents

Info

Publication number
JP2022533448A5
JP2022533448A5 JP2021569494A JP2021569494A JP2022533448A5 JP 2022533448 A5 JP2022533448 A5 JP 2022533448A5 JP 2021569494 A JP2021569494 A JP 2021569494A JP 2021569494 A JP2021569494 A JP 2021569494A JP 2022533448 A5 JP2022533448 A5 JP 2022533448A5
Authority
JP
Japan
Prior art keywords
polynucleotide
vector
expression cassette
expression
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021569494A
Other languages
English (en)
Japanese (ja)
Other versions
JP7616668B2 (ja
JP2022533448A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/034171 external-priority patent/WO2020237130A1/en
Publication of JP2022533448A publication Critical patent/JP2022533448A/ja
Publication of JP2022533448A5 publication Critical patent/JP2022533448A5/ja
Application granted granted Critical
Publication of JP7616668B2 publication Critical patent/JP7616668B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021569494A 2019-05-22 2020-05-22 Ube3a遺伝子および発現カセットならびにそれらの使用 Active JP7616668B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851411P 2019-05-22 2019-05-22
US62/851,411 2019-05-22
PCT/US2020/034171 WO2020237130A1 (en) 2019-05-22 2020-05-22 Ube3a genes and expression cassettes and their use

Publications (3)

Publication Number Publication Date
JP2022533448A JP2022533448A (ja) 2022-07-22
JP2022533448A5 true JP2022533448A5 (enExample) 2023-10-31
JP7616668B2 JP7616668B2 (ja) 2025-01-17

Family

ID=73458642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569494A Active JP7616668B2 (ja) 2019-05-22 2020-05-22 Ube3a遺伝子および発現カセットならびにそれらの使用

Country Status (12)

Country Link
US (2) US12465655B2 (enExample)
EP (1) EP3973059A4 (enExample)
JP (1) JP7616668B2 (enExample)
KR (1) KR20210158859A (enExample)
CN (1) CN114127296B (enExample)
AU (1) AU2020279387B2 (enExample)
CA (1) CA3139678A1 (enExample)
EA (1) EA202193214A1 (enExample)
IL (1) IL287943A (enExample)
MX (1) MX2021014248A (enExample)
SG (1) SG11202112470YA (enExample)
WO (1) WO2020237130A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022119890A1 (en) * 2020-12-01 2022-06-09 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
JP2025520199A (ja) * 2022-06-07 2025-07-01 キチョー インク. 発現を調節するための薬剤
US20240261438A1 (en) * 2023-02-08 2024-08-08 Ginkgo Bioworks, Inc. Gene therapy for angelman syndrome
WO2025128816A1 (en) * 2023-12-13 2025-06-19 Kicho Inc. Methods of modulating expression of ube3a gene
WO2025213123A1 (en) * 2024-04-05 2025-10-09 Encoded Therapeutics, Inc. Methods and compositions for increasing expression of ube3a

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
AU774706B2 (en) 1998-09-22 2004-07-08 Johns Hopkins University, The Methods for large-scale production of recombinant AAV vectors
DE69936104T2 (de) 1998-11-05 2008-01-17 The Trustees Of The University Of Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
ES2809199T3 (es) * 2012-06-25 2021-03-03 Ionis Pharmaceuticals Inc Modulación de la expresión de UBE3A-ATS
PL2900686T3 (pl) 2012-09-28 2021-01-25 The University Of North Carolina At Chapel Hill Wektory aav ukierunkowane na oligodendrocyty
KR20250012194A (ko) * 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
WO2015060722A1 (en) * 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
AU2015349759B2 (en) 2014-11-21 2022-01-06 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
CA2984629C (en) 2015-05-07 2024-06-18 University Of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome
US20180346531A1 (en) * 2015-09-15 2018-12-06 Regents Of The University Of California Compositions and methods for delivering biotherapeutics
HK1258434A1 (zh) 2015-11-12 2019-11-08 F. Hoffmann-La Roche Ag 来自灵长类物种的标准化神经元细胞测定试验
CA3068304A1 (en) 2017-06-28 2019-01-03 University Of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome
EP3941530A4 (en) 2019-03-21 2022-12-14 PTC Therapeutics, Inc. ANGELMAN SYNDROME TREATMENT VECTOR AND PROCEDURES
AU2020334924A1 (en) 2019-08-22 2022-04-07 The Regents Of The University Of California UBE3A for the treatment of Angelman syndrome

Similar Documents

Publication Publication Date Title
US20220331409A1 (en) Factor ix gene therapy
US20240197918A1 (en) Tissue-targeted modified aav capsids and methods of use thereof
JP2022549380A5 (enExample)
JP2021087431A5 (enExample)
JP2024009857A5 (enExample)
JP2021513999A5 (enExample)
JP2022524434A5 (enExample)
JP2023514242A5 (enExample)
JP2021533805A5 (enExample)
JP2022551744A5 (enExample)
CN116732069A (zh) 酸性α-葡萄糖苷酶变体及其用途
CA3158518A1 (en) Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases
WO2022226375A1 (en) Tissue-targeted modified aav capsids and methods of use thereof
JP2023503850A5 (enExample)
JP2021534766A5 (enExample)
KR20250115422A (ko) 반복적 요소의 적절한 패키징을 위한 아데노 연관 바이러스 벡터
KR20240095165A (ko) 근이영양증의 치료
JP2023059858A5 (enExample)
JP2024530023A5 (enExample)
Ortolano et al. Present and future of adeno associated virus based gene therapy approaches
Chen Adeno-associated virus vectors for human gene therapy
JP2023542131A5 (enExample)
JP2023515795A5 (enExample)
JP2025508987A (ja) Glp-1受容体アゴニスト融合物の送達のためのaavベクター
JP2025515356A5 (enExample)